Developing Canada's Research Base for Harm Reduction and Health Equity Approaches to HIV Prevention and Treatment

Jeannie Shoveller, PhD,¹ Kora DeBeck, MPP,² Julio Montaner, MD, DSc (hon), FRCPC, FCCP, FACP, FRSC^{2,3}

ABSTRACT

In the area of infectious disease control, Canadian research efforts to address the HIV epidemic in Vancouver's Downtown East Side neighbourhood have fueled the development of harm reduction and health equity perspectives worldwide. These research efforts have, in turn, reshaped the field of public health approaches to HIV prevention and control. As a result of the intensive and sustained research initiatives led by Canadian scientists Drs. Thomas Kerr and Evan Wood, the 'HIV problem' and public health responses to it have been radically reconceptualized – shifting from an exclusive focus on individual choice towards asking fundamental questions about our society and the structural features that put people at risk for contracting HIV. Their research on harm reduction and health equity related to HIV vulnerability and outcomes has informed and shaped: 1) the establishment of North America's first supervised injection facility, Insite, located in Vancouver's Downtown East Side neighbourhood; 2) dramatic changes to Vancouver's needle exchange policies; 3) HIV treatment approaches among injection drug using populations (IDU). By drawing attention to the ways in which Canadian health care policies and programs can be restructured to better support the health of vulnerable populations, the work of Drs. Kerr and Wood represents a uniquely Canadian public health milestone.

Key words: Infectious disease transmission; HIV; drug addiction; harm reduction; injection drug use; supervised injecting facilities

La traduction du résumé se trouve à la fin de l'article.

Can J Public Health 2010;101(6):442-44.

In the area of infectious disease control, Canadian research efforts to address the HIV epidemic in Vancouver's Downtown East Side neighbourhood have fueled the development and advancement of harm reduction and health equity perspectives worldwide. These research efforts have, in turn, reshaped the field of public health approaches to HIV prevention and treatment.

As a result of the intensive and sustained research initiatives led by two young Canadian scientists working at the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE), Drs. Thomas Kerr and Evan Wood, the 'HIV problem' and public health responses to it have been radically reconceptualized – shifting from an exclusive focus on individual choice towards asking fundamental questions about our society and the structural factors that put people at risk for contracting HIV. Methodological advances made at the BC-CfE have been instrumental in this area, including the launch of multiple studies involving highly vulnerable individuals (e.g., people who inject drugs, sex workers, people who are HIV-positive, street-engaged youth, etc.), as well as the use of innovative ethno-epidemiological techniques to illuminate for policy-makers as well as front-line public health practitioners the links between context, structure and individual health outcomes. More specifically, their research on harm reduction and health equity related to HIV vulnerability and outcomes has informed and shaped: 1) the establishment of North America's first supervised injection facility, Insite, located in Vancouver's Downtown East Side neighbourhood; 2) dramatic changes to Vancouver's needle exchange policies;

3) treatment approaches for HIV-seropositive individuals who use injection drugs (IDU).

In September 2003, in the wake of an explosive outbreak of HIV and high rates of overdose death among local IDU, Vancouver opened a pilot supervised injection facility (SIF). Before this facility was established, however, Drs. Kerr and Wood and their team at the BC-CfE developed a rationale for establishing a SIF research pilot study and undertook extensive feasibility work, which was instrumental in gaining approval to open a facility of this kind.¹⁻⁵ Once the facility was established, Drs. Kerr and Wood developed and implemented an evaluation framework which involved prospective cohort studies, data linkages to government-held data as well as ethnographic research.⁶ To date, over 30 studies evaluating the SIF have been published in top-ranking medical and public health journals (e.g., *The New England Journal of Medicine*, *The Lancet*, *The British*

Author Affiliations

1. School of Population and Public Health, University of British Columbia, Vancouver, BC

2. British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC

3. Division of AIDS, Department of Medicine, University of British Columbia, Vancouver, BC

The authors developed the case for this nomination based on a large body of scientific evidence generated by Drs. Kerr and Wood and their collaborators at the BC Centre for Excellence in HIV/AIDS as well as research collaborations undertaken elsewhere in Canada and internationally.

Correspondence: Dr. Julio Montaner, BC Centre for Excellence in HIV/AIDS, 608-1081 Burrard Street, Vancouver, BC V6Z 1Y6, Tel: 604-806-8036, E-mail: jmontaner@cfenet.ubc.ca

Acknowledgements: We thank Kelly Hsu, Deborah Graham, Tricia Collingham and Carmen Rock for their assistance.

Medical Journal, and *The Canadian Medical Association Journal*).⁷⁻¹⁰ These studies have documented benefits including reductions in HIV risk behaviours, decreases in overdose mortality and improved access to addiction treatment. The evaluation results also have shown that many concerns regarding potential negative outcomes of the SIF are unwarranted. References for all SIF evaluation studies can be found on the BC-CfE Urban Health Research Initiative Website at: <http://uhri.cfenet.ubc.ca/content/view/57/92/>.

In addition to conducting rigorous research on the Vancouver SIF, Drs. Kerr and Wood have also undertaken extensive knowledge translation (KT) activities. This included engaging extensively with the media to translate SIF-related research findings into improved knowledge among the public. For example, in 2006 alone, Dr. Kerr participated in more than 100 print, radio and television interviews with local, national and international media outlets. Drs. Kerr and Wood also raised awareness among multiple audiences by delivering dozens of SIF-based presentations and developed plain language summaries of SIF findings (see: <http://uhri.cfenet.ubc.ca/content/view/57/92/>). These activities were critical in maximizing informed public engagement about issues relating to HIV prevention and control.

Drs. Kerr and Wood's research and KT efforts specific to the SIF have had a substantial impact on promoting improvements in the health of Canadians and the health care system. It has been cited that the research by Drs. Kerr and Wood, along with resulting media coverage and public outcry, was the leading factor in the federal government delaying the expected closure of the facility and instead giving the facility an 18-month extension. Through their work, Drs. Kerr and Wood have supported the continuation of the SIF, which is helping to promote efficiency in the health care system. Indeed, several of the SIF evaluation studies indicated that the facility is acting as a critical point of care for the highest-risk individuals and that SIF staff are performing an important function by linking individuals with appropriate preventive health care services.

Drs. Kerr and Wood have also made significant contributions to our understanding of needle exchange program (NEP) delivery and efficacy, which has led to dramatic changes in Vancouver's NEP programs, as well as subsequent declines in HIV incidence. In the wake of Vancouver's HIV outbreak in the mid-1990s, some international experts questioned the benefits of needle exchange, as a high-volume needle exchange had operated in Vancouver since the late 1980s. Using their established research infrastructure, Drs. Kerr and Wood undertook a number of studies to investigate why HIV infections had increased so dramatically in the 1990s despite an established needle exchange system. Their work revealed that a number of programmatic deficiencies with Vancouver's NEP drove the outbreak. They demonstrated that the most important reason why individuals used contaminated syringes in Vancouver was difficulty in accessing sterile syringes.¹¹ The existing NEP system was not distributing enough syringes because of restrictive rules and the fact that the exchange was closed at night.¹² Subsequent research conducted by Drs. Kerr and Wood demonstrated that other NEP operated by other drug users that were open at night had more success in reaching IDU at highest risk of HIV infection.^{13,14} After engaging in extensive knowledge translation activities to disseminate these findings,^{15,16} the Vancouver Coastal Health Authority made fundamental reforms to their needle exchange program from 2000-2002, based on the findings and recommendations of Drs. Kerr and Wood. Changes included decentralizing and expanding

the NEP and moving away from a focus on exchange toward a focus on distribution. Limits on the number of syringes that could be obtained were removed and there was an expansion in the number of sites and methods used for distribution, including the involvement of peer groups. In a study recently published in the *American Journal of Public Health*, Drs. Kerr and Wood evaluated the impact of these reforms and found that the restructuring was associated with a dramatic reduction in rates of syringe borrowing (20% in 1998 to 9% in 2005) and HIV incidence.¹⁷ These declines reveal the extent to which this public health intervention made an impact on the health of vulnerable populations. The large body of research generated by Drs. Kerr and Wood has been instrumental in clarifying our understanding of Vancouver's HIV epidemic and the factors that contributed to it. Without this research to inform more effective NEP distribution, public health efforts to stem the tide of this epidemic would have been severely hampered.

Drs. Kerr and Wood's research has also made a substantial impact on the delivery of treatment for HIV infection for IDU. By identifying inequalities in access to antiretroviral therapy (ART) among IDU – including a failure by physicians to initiate ART for IDU when clinically indicated¹⁸ – and high rates of medically inappropriate ART prescriptions by physicians,¹⁹ better practices were put in place to promote more equitable health service delivery. In addition, Drs. Kerr and Wood documented that IDU were more likely to die without having ever received HIV therapy.^{20,21} Conversely, they also documented that despite physician reluctance to start IDU on HIV therapy for fear of treatment failure or the development of viral resistance, IDU adherent to appropriate ART experienced the same health benefits as comparably adherent non-IDU patients.^{22,23} Other research activities led by Drs. Kerr and Wood identified important social and structural barriers to HIV treatment access among IDU.^{24,25} For example, they documented the benefits of linking HIV therapy with addiction treatment²⁶ and the barriers that incarceration can have on treatment access and success.²⁷⁻²⁹

In part as a result of the body of work created by Drs. Kerr and Wood, current best practice for treating HIV-positive IDU in British Columbia are now based on comprehensive, evidence-based approaches to health care. Indeed, uptake of HIV therapy among IDU has increased dramatically, and it is now the policy of all health authorities in British Columbia, with the full support of the provincial government of BC, to target IDU for HIV treatment.^{30,31}

Through their research excellence, Drs. Kerr and Wood have generated a substantial body of literature that has guided and supported the development and implementation of equitable HIV prevention and treatment policies and programs for people who use illicit drugs. From their work on the supervised injection facility, to needle exchange programs and HIV treatment, Drs. Kerr and Wood have demonstrated that individual behaviour is not the pre-eminent factor shaping health outcomes. By drawing attention to the ways in which our policies and programs can be restructured to better support the health of vulnerable populations, the work of Drs. Kerr and Wood represents a uniquely Canadian public health milestone that is worthy of recognition and celebration.

REFERENCES

1. Kerr T, Wood E, Small D, Palepu A, Tyndall MW. Potential use of safer injecting facilities among injection drug users in Vancouver's downtown eastside. *CMAJ* 2003;169:759-63.

2. Wood E, Tyndall M, Spittal P, Li K, Kerr T, Hogg R, et al. Unsafe injection practices in a cohort of injection drug users in Vancouver: Could safer injecting rooms help? *CMAJ* 2001;165:405-10.
3. Wood E, Kerr T, Spittal P, Small W, Tyndall M, Li K, et al. The potential public health and community impacts of safer injecting facilities: Evidence from a cohort of injection drug users. *AIDS* 2003;32:2-8.
4. Wood E, Kerr T, Montaner J, Strathdee S, Wodak A, Hankins C, et al. Rationale for evaluating North America's first medically supervised safer-injecting facility. *The Lancet Infectious Diseases* 2004;4:301-6.
5. Kerr T, Wood E, Palepu A, Wilson D, Schechter MT, Tyndall MW. Responding to an explosive HIV epidemic driven by frequent cocaine injection: Is there a role for safe injecting facilities? *J Drug Iss* 2003;33:579-608.
6. Wood E, Kerr T, Lloyd-Smith E, Buchner C, Marsh DC, Montaner JS, Tyndall MW. Methodology for evaluating Insite: Canada's first medically supervised safer injection facility for injection drug users. *Harm Reduct J* 2004;1:9.
7. Kerr T, Stoltz J, Tyndall M, Li K, Zhang R, Montaner J, Wood E. Impact of a medically supervised safer injection facility on community drug use patterns: A before and after study. *BMJ* 2006;332:220.
8. Kerr T, Tyndall M, Li K, Montaner J, Wood E. Safer injection facility use and syringe sharing in injection drug users. *The Lancet* 2005;366:316-18.
9. Wood E, Tyndall M, Zhang R, Stoltz J, Lai C, Montaner J, Kerr T. Attendance at supervised injecting facilities and use of detoxification services. *N Engl J Med* 2006;354:2512-14.
10. Wood E, Tyndall MW, Montaner JS, Kerr T. Summary of findings from the evaluation of a pilot medically supervised safer injecting facility. *CMAJ* 2006;175:1399-404.
11. Wood E, Tyndall MW, Spittal PM, Li K, Hogg RS, Montaner JS, et al. Factors associated with persistent high-risk syringe sharing in the presence of an established needle exchange programme. *AIDS* 2002;16:941-43.
12. Wood E, Tyndall MW, Spittal PM, Li K, Hogg RS, O'Shaughnessy MV, Schechter MT. Needle exchange and difficulty with needle access during an ongoing HIV epidemic. *Int J Drug Policy* 2002;13:95-102.
13. Wood E, Kerr T, Spittal PM, Small W, Tyndall MW, O'Shaughnessy MV, Schechter MT. An external evaluation of a peer-run "unsanctioned" syringe exchange program. *J Urban Health* 2003;80:455-64.
14. Hayashi K, Wood E, Wiebe L, Qi J, Kerr T. An external evaluation of a peer-run outreach-based syringe exchange in Vancouver, Canada. *Int J Drug Policy* 2010;21:418-21.
15. Wood E, Kerr T. Needle exchange and the HIV outbreak among injection drug users in Vancouver, Canada. *Subst Use Misuse* 2006;41:841-43.
16. Kerr T, Wood E. Needle exchange programs and HIV outbreak among injection drug users in Vancouver, Canada: Addressing some common misperceptions. Toronto, ON: Canadian HIV/AIDS Legal Network, 2005.
17. Kerr T, Small W, Buchner C, Zhang R, Li K, Montaner J, Wood E. Syringe sharing and HIV incidence among injection drug users and increased access to sterile syringes. *Am J Public Health* 2010;100:1449-53.
18. Wood E, Hogg RS, Bonner S, Kerr T, Li K, Palepu A, et al. Staging for antiretroviral therapy among HIV-infected drug users. *JAMA* 2004;292:1175-77.
19. Wood E, Hogg RS, Kerr T, Bonner S, Strathdee SA, Palepu A, Montaner JS. Rates of inappropriate antiretroviral prescription among injection drug users. *Harm Reduct J* 2007;4:2.
20. Wood E, Montaner JS, Chan K, Tyndall MW, Schechter MT, Bangsberg D, et al. Socioeconomic status, access to triple therapy, and survival from HIV-disease since 1996. *AIDS* 2002;16:2065-72.
21. Wood E, Montaner JS, Tyndall MW, Schechter MT, O'Shaughnessy MV, Hogg RS. Prevalence and correlates of untreated human immunodeficiency virus type 1 infection among persons who have died in the era of modern antiretroviral therapy. *J Infect Dis* 2003;188:1164-70.
22. Wood E, Schechter MT, Tyndall MW, Montaner JS, O'Shaughnessy MV, Hogg RS. Antiretroviral medication use among injection drug users: Two potential futures. *AIDS* 2000;14:1229-35.
23. Wood E, Hogg RS, Lima VD, Kerr T, Yip B, Marshall BD, Montaner JS. Highly active antiretroviral therapy and survival in HIV-infected injection drug users. *JAMA* 2008;300:550-54.
24. Wood E, Kerr T, Tyndall MW, Montaner JS. A review of barriers and facilitators of HIV treatment among injection drug users. *AIDS* 2008;22:1247-56.
25. Wood E, Kerr T, Montaner J. HIV treatment, injection drug use, and illicit drug policies. *The Lancet* 2007;370:8-10.
26. Wood E, Hogg RS, Kerr T, Palepu A, Zhang R, Montaner JS. Impact of accessing methadone on the time to initiating HIV treatment among antiretroviral-naïve HIV-infected injection drug users. *AIDS* 2005;19:837-39.
27. Small W, Wood E, Betteridge G, Montaner J, Kerr T. The impact of incarceration upon adherence to HIV treatment among HIV-positive injection drug users: A qualitative study. *AIDS Care* 2009;21:708-14.
28. Kerr T, Marshall A, Walsh J, Palepu A, Tyndall M, Montaner J, et al. Determinants of HAART discontinuation among injection drug users. *AIDS Care* 2005;17:539-49.
29. Kerr T, Palepu A, Barnes G, Walsh J, Hogg R, Montaner J, et al. Psychosocial determinants of adherence to highly active antiretroviral therapy among injection drug users in Vancouver. *Antivir Ther* 2004;9:407-14.
30. Montaner J, Lima V, Barrios R, Yip B, Wood E, Kerr T, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: A population-based study. *The Lancet* 2010;376:532-39.
31. Ministry of Health Services. News release: B.C. to seek and treat most vulnerable HIV patients. Feb 4, 2010. Available at: http://www2.news.gov.bc.ca/news_releases_2009-2013/2010HSERV0006-000123.htm (Accessed June 25, 2010).

RÉSUMÉ

Dans le domaine de la lutte contre les maladies infectieuses, les efforts de recherche canadiens pour contrer l'épidémie de VIH dans le quartier Downtown Eastside de Vancouver ont favorisé le développement de perspectives de réduction des méfaits et d'équité en santé partout dans le monde. Ces efforts ont à leur tour transformé les approches de santé publique à l'égard de la prévention et de la lutte contre le VIH. En raison des initiatives de recherche intensives et soutenues dirigées par deux scientifiques canadiens, Thomas Kerr et Evan Wood, le « problème du VIH » et la réponse de la santé publique à ce problème ont été radicalement reconceptualisés. On est passé d'une optique exclusivement axée sur le choix personnel à la formulation de questions fondamentales sur notre société et les aspects structurels qui exposent les gens à contracter le VIH. Leurs recherches sur la réduction des méfaits et l'équité en santé par rapport à la vulnérabilité au VIH et aux résultats cliniques de l'exposition au virus ont été étayés et façonnés : 1) l'établissement du premier site d'injection supervisé en Amérique du Nord, Insite, dans le quartier Downtown Eastside; 2) les changements radicaux dans les politiques d'échange de seringues de la ville de Vancouver; et 3) les approches de traitement du VIH dans les populations consommatrices de drogues par injection. En attirant l'attention sur les façons possibles de restructurer les politiques et les programmes de soins de santé au Canada pour mieux protéger la santé des populations vulnérables, les travaux de Kerr et Wood représentent un jalon typiquement canadien de la santé publique.

Mots clés : transmission de maladies infectieuses; VIH; dépendance; réduction des méfaits; toxicomanie intraveineuse; sites d'injection supervisés